Project Grant R01HL171326
Award Date 8/1/24
Completion Date 7/31/28
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $2,442,173 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) to identify genes and pathways that influence the risk of vascular diseases such as coronary artery disease (CAD) and pulmonary arterial hypertension (PAH). The 5-year award, effective August 15, 2025, will leverage innovative CRISPR genomics approaches to characterize gene...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $331,344.00 to The Leland Stanford Junior University to investigate the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its impact on smooth muscle cell phenotypic modulation. The research aims to determine how PRDM16, an epigenetic modifier, regulates the transition of smooth muscle cells into protective "fibromyocytes"...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $232,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University to conduct a 30-year follow-up study of the Coronary Artery Calcium Consortium (CAC Consortium). The goal of the project is to quantify long-term survival and cardiovascular mortality risk prediction for individuals aged 30-59 based on their baseline coronary artery calcium (CAC) scores. The research aims to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $761,042 to the University of Pittsburgh to conduct research on the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The key objectives are to: 1) define how the DNA damage response promotes vascular calcification, and 2) determine how reduced adenosine production alters arginine methylation to upregulate osteogenic gene...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $165,888 Project Grant to The Leland Stanford Junior University (Stanford University) to conduct research on the role of the ZEB1 transcription factor in the development of coronary artery disease (CAD). The primary objective is to characterize and establish the causal role of ZEB1 in atherosclerosis development. The research will use a ZEB1 knockout mouse model to determine the transcriptional, epigenetic, and plaque...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. Specifically, the project aims to improve the efficacy of in-situ reprogramming of scar fibroblasts into cardiomyocytes through three key objectives: Investigating the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $450,000 in funding to Old Dominion University to investigate the relationship between disturbed sleep and the development of vulnerable atherosclerotic plaques. The primary objectives are to: 1) examine the role of NADPH-dependent oxidative stress in accelerating the formation of vulnerable atherosclerotic plaques in...
- This $590,283 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The key objectives are to: 1) Identify failure modes in 2D cardiomyocyte differentiation through integrated single-cell transcriptomics and epigenomics, and 2) Develop control strategies to enhance the reproducibility of human...